IL282311A - Raboxetine for the treatment of narcolepsy - Google Patents

Raboxetine for the treatment of narcolepsy

Info

Publication number
IL282311A
IL282311A IL282311A IL28231121A IL282311A IL 282311 A IL282311 A IL 282311A IL 282311 A IL282311 A IL 282311A IL 28231121 A IL28231121 A IL 28231121A IL 282311 A IL282311 A IL 282311A
Authority
IL
Israel
Prior art keywords
reboxetine
treat narcolepsy
narcolepsy
treat
Prior art date
Application number
IL282311A
Other languages
English (en)
Hebrew (he)
Inventor
Tabuteau Herriot
Original Assignee
Axsome Therapeutics Inc
Tabuteau Herriot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc, Tabuteau Herriot filed Critical Axsome Therapeutics Inc
Publication of IL282311A publication Critical patent/IL282311A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL282311A 2018-10-15 2021-04-13 Raboxetine for the treatment of narcolepsy IL282311A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862745956P 2018-10-15 2018-10-15
PCT/US2019/056134 WO2020081461A1 (en) 2018-10-15 2019-10-14 Use of reboxetine to treat narcolepsy

Publications (1)

Publication Number Publication Date
IL282311A true IL282311A (en) 2021-05-31

Family

ID=70284075

Family Applications (1)

Application Number Title Priority Date Filing Date
IL282311A IL282311A (en) 2018-10-15 2021-04-13 Raboxetine for the treatment of narcolepsy

Country Status (16)

Country Link
EP (1) EP3866768A4 (ja)
JP (1) JP2022504975A (ja)
KR (2) KR20240119194A (ja)
CN (1) CN112888430A (ja)
AU (2) AU2019361915A1 (ja)
BR (1) BR112021007019A2 (ja)
CA (1) CA3115983A1 (ja)
CL (1) CL2021000924A1 (ja)
CO (1) CO2021004681A2 (ja)
CR (1) CR20210514A (ja)
EC (1) ECSP21031200A (ja)
IL (1) IL282311A (ja)
MX (1) MX2021004207A (ja)
PE (1) PE20211199A1 (ja)
SG (1) SG11202103588WA (ja)
WO (1) WO2020081461A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
KR20230055668A (ko) * 2021-10-19 2023-04-26 단국대학교 천안캠퍼스 산학협력단 레복세틴을 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
EP1763354A2 (en) * 2004-06-09 2007-03-21 Pfizer Limited Use of reboxetine for the treatment of pain
SG11201507121RA (en) * 2013-03-13 2015-10-29 Aerial Biopharma Llc Treatment of cataplexy

Also Published As

Publication number Publication date
EP3866768A4 (en) 2022-01-05
JP2022504975A (ja) 2022-01-13
AU2019361915A1 (en) 2021-05-13
CO2021004681A2 (es) 2021-06-21
EP3866768A1 (en) 2021-08-25
CL2021000924A1 (es) 2021-09-03
CA3115983A1 (en) 2020-04-23
KR20210071046A (ko) 2021-06-15
ECSP21031200A (es) 2021-05-31
CN112888430A (zh) 2021-06-01
BR112021007019A2 (pt) 2021-07-13
SG11202103588WA (en) 2021-05-28
CR20210514A (es) 2021-11-12
PE20211199A1 (es) 2021-07-01
AU2023200917A1 (en) 2023-03-23
WO2020081461A1 (en) 2020-04-23
KR20240119194A (ko) 2024-08-06
MX2021004207A (es) 2021-08-11

Similar Documents

Publication Publication Date Title
IL286888A (en) Use of pyridofidine to treat depression and anxiety
IL255615A (en) Use of cannabis to treat fibromyalgia, methods and compositions thereof
IL282311A (en) Raboxetine for the treatment of narcolepsy
GB201804514D0 (en) Treatment of pyroptosis
HK1252816A1 (zh) Tlr8激活劑治療癌症的應用
HK1251009B (zh) 用於治療癌症的治療組合物
ZA201907401B (en) Treatment of adipocytes
ZA202003785B (en) Use of coriobacteriia to promote gut health
IL271164A (en) Use of vibragron to treat overactive bladder
ZA201903795B (en) Treatment of water
GB201804515D0 (en) Treatment of necroptosis
IL270362B (en) Glaucoma treatment
ZA201906238B (en) New therapeutical use of h3-ligands
IL259781A (en) Uses of pyrimido-pyridazinones to treat cancer
GB201907305D0 (en) Treatment of conditions
ZA202105399B (en) Use of spiropidion
IL282869A (en) Use of tibozenib to treat patients with resistant cancer
IL278876A (en) Use of vibegron to treat pain associated with irritable bowel syndrome
IL273543A (en) A new treatment for SMA
EP4003283C0 (en) TREATMENT OF INFLAMMATORY SKIN CONDITIONS
GB201917253D0 (en) Treatment of conditions
IL290983A (en) Treatment methods
ZA201904327B (en) Treatment of skin conditions
GB201918853D0 (en) Methods of treatment
GB201821093D0 (en) Treatment of hydrocarbons